1982952180

1982952180 was paid $463K by Medicaid between Jan 2018 and Nov 2022, across 35 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 41% of everything it billed.

33Billing provider info1982952180

33aNPI1982952180

33bProvider type—

28Total paid$463K

24GClaims68,698

24DCodes billed35

24AFirst – last monthJan 2018 – Nov 2022

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	62,126	$240K
2019	3,367	$51K
2020	115	$9K
2021	281	$16K
2022	2,809	$147K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	41%	7,734	5,964	$191K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	19%	2,179	1,671	$87K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	10%	2,427	2,110	$48K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	7.7%	498	432	$35K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.6%	497	431	$12K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.2%	331	228	$10K
80336		1.7%	2,038	1,780	$8K
80372		1.6%	2,465	2,122	$8K
80373		1.6%	2,465	2,122	$8K
80367		1.6%	2,037	1,779	$7K
80368		1.6%	2,061	1,796	$7K
80366		1.6%	2,055	1,791	$7K

23 more codes

80370		1.6%	2,062	$7K
80323		1.6%	2,059	$7K
80320		1.2%	2,072	$6K
80171		1.1%	2,071	$5K
82540		<1%	2,044	$2K
80346		<1%	2,003	$642.36
80364		<1%	2,004	$640.89
80361		<1%	2,003	$609.35
80354		<1%	2,002	$479.59
80348		<1%	2,003	$479.59
80365		<1%	2,003	$416.03
80325		<1%	1,991	$415.65
80358		<1%	2,003	$414.68
80359		<1%	1,991	$410.80
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	243	$404.40
80349		<1%	2,019	$367.58
80345		<1%	1,992	$355.44
80356		<1%	1,573	$315.89
80351		<1%	1,591	$314.54
80353		<1%	1,594	$311.84
83992		<1%	1,599	$277.28
80362		<1%	1,981	$41.00
82542		0%	1,008	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.